Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...

Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...

A brand-new event has just launched in the renowned World ADC Series – the inaugural ADC Payload Summit is taking place this May in Boston (21-23)! The ADC payload landscape is shifting rapidly.

Tubulis continues expansion of its clinical pipeline with a second ADC drug candidate entering the clinic TUB-030 is a next-generation ADC targeting 5T4 with an exatecan payload, developed based ...

Tubulis has dosed the first subject in the multicentre Phase I/IIa 5-STAR 1-01 trial to clinically evaluate its second drug ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program.

To stay up to date on Akari's recent developments on the Webull Corporate Connect Services Platform, current Webull users can ...

TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration combines Biocytogen’s RenLite ...

Araris’ ADC platform, AraLinQTM, boasts the ability to attach more than one payload to an antibody. Recently, BeiGene and Legend Biotech have been trading at what analysts described as a ...